^
Association details:
| Biomarker: | HRAS mutation |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | Zarnestra (tipifarnib) (CXCL12 inhibitor, Farnesyl transferase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Study of Tipifarnib in Patients With Previously-Treated, Advanced, HRAS Mutant Urothelial Carcinoma
Excerpt:
...Subject has a tumor that carries a missense HRAS mutation according to a standard methodology using Illumina HiSeqTM....
Trial ID:
Source:
Title:
Tipifarnib, a farnesyltransferase inhibitor, for metastatic urothelial carcinoma harboring HRAS mutations.
Published date:
05/25/2020
Excerpt:
Oral tipifarnib showed a manageable safety profile and encouraging anti-tumor efficacy against treatment-refractory UC containing HRAS mutations.
DOI:
10.1200/JCO.2020.38.15_suppl.5086
Trial ID:
Source:
Title:
Preliminary activity of tipifarnib in tumors of the head and neck, salivary gland and urothelial tract with HRAS mutations.
Published date:
05/13/2020
Excerpt:
In IST-01, 224 UC pts were screened of whom 16 (7%) carried HRAS mutations and 15 of those were enrolled into the study. Five responses were observed in 12 evaluable UC pts (42%) and 3 additional pts had tumor size reduction. Median PFS was 5.1 months.
DOI:
10.1200/JCO.2020.38.15_suppl.6504
Trial ID:
